|
Cell line
|
Basal CXCR4 expression (cpm/105 cells)
|
Drug treatment
|
|---|
| | |
5-FU
|
Cis
|
Vin
|
MTX
|
|---|
| | |
Maximal decrease (% from control)
|
|
HT-29
|
470 ± 52
|
75 ± 6.1*
|
72 ± 6.3*
|
75 ± 12*
|
56 ± 7.6*
|
|
T84
|
220 ± 53
|
42 ± 15
|
48 ± 22
|
27 ± 4.4
|
39 ± 21
|
|
HRT-18
|
62 ± 27
|
59 ± 18
|
29 ± 11
|
76 ± 8.4
|
63 ± 27
|
|
SW480
|
230 ± 41
|
24 ± 13
|
32 ± 13
|
71 ± 7.6*
|
24 ± 6.4
|
|
SW620
|
80 ± 29
|
70 ± 7.0
|
77 ± 13*
|
72 ± 18
|
73 ± 3.0
|
- The relative basal cell-surface protein expression for each cell line was summarized from 8–28 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CXCR4 was determined by radioimmunobinding assay 48 h later. Maximal decrease of CXCR4 was recorded from 3–8 independent dose–response experiments for each drug and cell line. Data are shown as mean % decreases ± SE. *, significant % decrease due to drug, P < 0.05 using paired t-test
